Much of the news surrounding Dallas-based Neos Therapeutics, Inc. this year has centered on the company’s raising of new capital, including $8 million in new funding back in January, and an additional $15 million in funding in March, all in an effort to further bolster the companies commercialization efforts into new oral drug delivery technologies. Now, the company has announced that it has secured a key patent for its novel amphetamine ADHD products.
The new patent, designated as US Patent No. 8,709,491, will provide protection for the new technologies until 2032. According to a company press release, the patent covers the development of an extended release (XR) amphetamine oral disintegrating tablet (ODT) as well as an extended release amphetamine liquid suspension. The company has indicated that it will file for FDA approval for both products within the next 12-15 months.
Vipin K. Garg, Ph.D., the CEO of Neos, notes that the securing of this new patent is a critical step in putting the company’s new technologies on a path toward successful commercialization: “We are pleased with the grant of this patent as it will provide protection for our amphetamine XR-ODT and amphetamine XR-suspension until June 2032,” he said . “We have begun to assess our options to commercialize these products in anticipation of FDA approval.”
Mark Tengler, Chief Technology Officer of Neos, explained that, particularly for AHDA-related therapies, the need for viable, effective extended-release drug delivery methods is essential for ensuring that drugs work optimally: “The Neos patent portfolio continues to grow as we continue to develop and utilize our platform drug delivery technologies,” he said. “Extended release and patient-friendly dosage forms are essential in the treatments of ADHD, and our technologies may provide this advantage.”